The agreement grants Nutrition 21 an exclusive license in the US and Canada for Coldizin, an ingredient combination, patented in the US and Europe, for enhancing upper-respiratory health.
The exclusive license allows Nutrition 21 to expand its product portfolio with a novel, clinically substantiated ingredient for the $4.5bn US cough and cold category.
Coldizin Ingredients and Special Markets vice president William Levi said that Coldizin is a clinically substantiated product that shows significant results in helping people deal with upper respiratory symptoms.
"Its innovative blend of the bioflavonoid troxerutin and zinc provides an option for either the dietary supplement or homeopathic segments," Levi said.
Provita CEO and chairman Carsten Waern said that they are excited to have a professional partner in Nutrition 21, who understands the North American marketplace and is a well-established, credible player in the industry.
Nutrition21 president and CEO Michael Zeher said that this new product fits nicely into their expansion strategy by providing with an innovative and product patented for use in the cold and cough market segment and are delighted to have Provita as a partner.